Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other-Reference-Cited by-同舟云学术

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

Published:2014-02-17 Issue:9 Volume:55 Page:2165-2173
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Surget Sylvanie,Lemieux-Blanchard Emilie,Maïga Sophie,Descamps Géraldine,Le Gouill Steven,Moreau Philippe,Amiot Martine,Pellat-Deceunynck Catherine

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.871277

Reference35 articles.

1. Bendamustine: Rebirth of an Old Drug

2. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

3. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

4. Bendamustine in patients with relapsed or refractory multiple myeloma

5. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals major role of BAX in BH3 mimetics response;Blood Journal;2023-12-14

2. A Supramolecular Nanomedicine Based on Bendamustine and MDM2‐Targeted D‐peptide Inhibitor for Breast Cancer Therapy;Advanced Healthcare Materials;2021-09-23

3. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network;Cancer;2021-06-28

4. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure;Leukemia Research;2019-10

5. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma;Frontiers in Genetics;2019-09-18